JP2016528283A5 - - Google Patents

Download PDF

Info

Publication number
JP2016528283A5
JP2016528283A5 JP2016536067A JP2016536067A JP2016528283A5 JP 2016528283 A5 JP2016528283 A5 JP 2016528283A5 JP 2016536067 A JP2016536067 A JP 2016536067A JP 2016536067 A JP2016536067 A JP 2016536067A JP 2016528283 A5 JP2016528283 A5 JP 2016528283A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
amiloride
onset
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016536067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528283A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/056011 external-priority patent/WO2015026339A1/en
Publication of JP2016528283A publication Critical patent/JP2016528283A/ja
Publication of JP2016528283A5 publication Critical patent/JP2016528283A5/ja
Pending legal-status Critical Current

Links

JP2016536067A 2013-08-21 2013-08-21 神経系損傷を減少させるための組成物及びその製造方法及び使用 Pending JP2016528283A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/056011 WO2015026339A1 (en) 2013-08-21 2013-08-21 Composition for reducing nervous system injury and method of making and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018090143A Division JP2018138592A (ja) 2018-05-08 2018-05-08 神経系損傷を減少させるための組成物及びその製造方法及び使用

Publications (2)

Publication Number Publication Date
JP2016528283A JP2016528283A (ja) 2016-09-15
JP2016528283A5 true JP2016528283A5 (enExample) 2017-04-13

Family

ID=52483995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536067A Pending JP2016528283A (ja) 2013-08-21 2013-08-21 神経系損傷を減少させるための組成物及びその製造方法及び使用

Country Status (5)

Country Link
EP (1) EP3035931B1 (enExample)
JP (1) JP2016528283A (enExample)
CN (2) CN110742891B (enExample)
HK (1) HK1221911A1 (enExample)
WO (1) WO2015026339A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105412932B (zh) * 2015-10-26 2019-08-16 上海交通大学医学院 含ASIC1a与RIP1结合抑制剂的制剂及其抑制神经元死亡的用途
CN112717135A (zh) * 2016-11-22 2021-04-30 上海交通大学医学院 酸敏感离子通道调控剂的用途
CN112888312A (zh) * 2018-08-28 2021-06-01 莫尔豪斯医学院 用于预防或降低短暂性脑缺血发作发病率的组合物及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0789859A (ja) * 1990-04-05 1995-04-04 Celtrix Pharmaceut Inc ピラジン誘導体を含む薬剤学的組成物と眼の新血管新生を阻止する治療法
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US7470718B2 (en) * 2000-10-03 2008-12-30 Albert Einstein College Of Medicine Of Yeshiva University Method for treating a demyelinating condition
CA2577268A1 (en) * 2004-08-30 2006-03-09 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
US8030442B2 (en) * 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
CA2622890A1 (en) * 2004-09-16 2006-03-30 Virogenomics, Inc. Treatment of ischemia
EP1904085B1 (en) * 2005-07-01 2020-09-02 Rosalind Franklin University of Medicine and Science Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke
US7892764B2 (en) * 2006-11-21 2011-02-22 Legacy Emanuel Hospital & Health Center System for seizure suppression
JP2008222603A (ja) * 2007-03-09 2008-09-25 Institute Of Physical & Chemical Research 神経変性疾患の予防・治療剤
US20090062309A1 (en) 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
KR20110016937A (ko) * 2008-05-15 2011-02-18 더 코카콜라 컴파니 개선된 일시적인 프로파일 및/또는 풍미 프로파일을 갖는 천연 및/또는 합성 고효능 감미제 조성물, 제형을 위한 방법, 및 용도
EP2322149A1 (en) * 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia

Similar Documents

Publication Publication Date Title
JP2016501828A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2016147915A5 (enExample)
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
JP2016106150A5 (enExample)
JP2015523407A5 (enExample)
JP2015532296A5 (enExample)
JP2015515475A5 (enExample)
JP2016028090A5 (enExample)
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
MX2015016416A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2017506624A5 (enExample)
GB2495676A (en) Use of binders for manufacturing storage stable formulations
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
IL292465B1 (en) Neuroactive compounds and methods of using them
HUE052332T2 (hu) Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2013166781A5 (enExample)
JP2015537009A5 (enExample)
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
JP2014504636A5 (enExample)
JP2016528283A5 (enExample)